CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST

pharmanewsdaily- July 26, 2020 0

US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a ... Read More

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

pharmanewsdaily- July 15, 2020 0

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More

FDA rejects Blueprint’s NDA for AYVAKIT for treatment of fourth-line GIST

pharmanewsdaily- May 15, 2020 0

Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA) for AYVAKIT (avapritinib) for the treatment of ... Read More